Compare LKQ & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LKQ | BLCO |
|---|---|---|
| Founded | 1998 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.0B |
| IPO Year | 2003 | 2022 |
| Metric | LKQ | BLCO |
|---|---|---|
| Price | $28.93 | $15.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $42.33 | $18.55 |
| AVG Volume (30 Days) | ★ 2.2M | 387.5K |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $13,651,000,000.00 | $5,101,000,000.00 |
| Revenue This Year | $2.01 | $8.63 |
| Revenue Next Year | $1.64 | $5.58 |
| P/E Ratio | $12.40 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $27.64 | $10.45 |
| 52 Week High | $43.47 | $18.92 |
| Indicator | LKQ | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 32.59 |
| Support Level | $28.36 | $14.39 |
| Resistance Level | $31.92 | $17.66 |
| Average True Range (ATR) | 0.78 | 0.48 |
| MACD | 0.06 | -0.13 |
| Stochastic Oscillator | 38.60 | 4.59 |
LKQ Corp is a world-wide distributor of vehicle products, including replacement parts, components and systems used in the repair and maintenance of vehicles, and specialty aftermarket products and accessories to improve the performance, functionality and appearance of vehicles. The company is organized into three operating segments: North America; Europe; and Specialty segment. It derives maximum revenue from Europe Segment. Europe segment is a provider of alternative vehicle replacement and maintenance products in Germany, the United Kingdom, the Benelux region (Belgium, Netherlands, and Luxembourg), Italy, Czech Republic, Austria, Slovakia, France and various other European countries.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.